Ursodeoxycholic acid — adverse effects and drug interactions

  title={Ursodeoxycholic acid — adverse effects and drug interactions},
  author={Wolfgang Hempfling and Karin Dilger and Ulrich Beuers},
  journal={Alimentary Pharmacology \& Therapeutics},
Background : Ursodeoxycholic acid is increasingly being used for the treatment of chronic cholestatic liver diseases. It appears to be generally well tolerated, but a systematic review on drug safety is lacking. 

[Ursodeoxycholic acid: A therapeutic niche in an internist's practice].

The results of the most important randomized controlled trials determining currently the evidence base for the efficiency and safety of using UDCA in the clinical picture of visceral diseases are given.

Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report

Co-administration of UDCA resulted in unquantifiable rilpivirine concentrations, but with no effects on darunavir plasma trough concentration, despite the fact that also the latter drug is a substrate of CYP3A enzymes.

Pathogenesis and Treatment of Pruritus in Cholestasis

Evidence-based therapeutic recommendations, including the use of anion exchange resins cholestyramine, colestipol and colesevelam, the microsomal enzyme inducer rifampicin, the opioid receptor antagonists naltrexone and naloxone, and the serotonin reuptake inhibitor sertraline, are provided.

Ursodeoxycholic acid in pregnancy ?

Primary biliary cholangitis: assessment and management strategies

Primary biliary cholangitis (PBC) is an autoimmune disease resulting in permanent damage to the bile ducts in the liver, often leading to symptoms including fatigue and itch that significantly impa...

American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy.

This literature review and the recommendations therein were prepared for the American Gastroenterological Association Institute Clinical Practice and Economics Committee. The paper was approved by

[Evaluation of therapeutic efficiency of various drugs of ursodeoxycholic acid in the treatment of biliary sludge].

The drug studied by us demonstrated high efficiency in relation to patients with BS, while there were minimal side effects, which led to a better tolerability of therapy.



Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications

Clinical and experimental work that may help to clarify possible mechanisms of action of UDCA in cholestasis and provide a clearer rationale for the administration ofUDCA in special cholESTatic disorders are summarized.

Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin‐clavulanate potassium (Augmentin®)‐induced intra‐hepatic cholestasis: report of two cases

It is suggested that ursodeoxycholic acid may be an effective treatment for drug‐associated cholestasis and improvement in patients' hyperbilirubinaemia and symptoms such as pruritus and fatigue.

Abdominal pain after taking ursodiol.

Two patients in whom severe right-upper-quadrant pain developed on repeated occasions within hours after taking ursodiol are reported.

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases

This review outlines the present knowledge of the modes of action of ursodeoxycholic acid, and presents data from clinical trials on its use in chronic liver diseases.

Drug reaction to ursodeoxycholic acid: lichenoid drug eruption in an infant using ursodeoxycholic acid for neonatal hepatitis.

This is the first infant case of lichenoid drug eruption associated with ursodeoxycholic acid reported in infants, and the lesions have resolved two months after the discontinuation of the drug.

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.

High-dose UDCA may be of clinical benefit in PSC, but trials with a larger number of participants and of longer duration are required to establish whether the effect of high- dose UDCA on liver biochemistry, histology, and cholangiography in patients with PSC is translated into improved long-term survival.

A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients

It is concluded that a single dose of ursodiol has little effect on CsA absorption in liver transplant patients and that an interaction in the intestinal lumen between these two drugs is unlikely.